Closing the Knowledge Gap: Hepatitis B Reactivation in Immunosuppression
نویسندگان
چکیده
منابع مشابه
Prevention of Hepatitis B reactivation in the setting of immunosuppression
Advances in the treatment of malignant and inflammatory diseases have developed over time, with increasing use of chemotherapeutic and immunosuppressive agents of a range of drug classes with varying mechanism and potency in their effects on the immune system. These advances have been met with the challenge of increased risk of hepatitis B virus (HBV) reactivation in susceptible individuals. Th...
متن کاملClosing the AI Knowledge Gap
AI researchers employ not only the scientific method, but also methodology from mathematics and engineering. However, the use of the scientific method – specifically hypothesis testing – in AI is typically conducted in service of engineering objectives. Growing interest in topics such as fairness and algorithmic bias show that engineering-focused questions only comprise a subset of the importan...
متن کاملReactivation of hepatitis B.
Reactivation of hepatitis B refers to the abrupt increase in hepatitis B virus (HBV) replication in a patient with inactive or resolved hepatitis B. Reactivation can occur spontaneously, but more typically is triggered by immunosuppressive therapy of cancer, autoimmune disease, or organ transplantation. Reactivation can be transient and clinically silent, but often causes a flare of disease tha...
متن کاملHepatitis B and Hepatitis C Reactivation in the Biologic Era
Hepatitis B (HBV) and hepatitis C (HCV) reactivation may occur after the use of biologic agents. During the last decade, utilization of biologics has changed the fate of many treated for cancer, autoimmune and connective tissue disease, maintenance of transplanted organs, and the prevention of graft-versus-host disease among others. HBV reactivation has been reported in up to 50% of HBV carrier...
متن کاملBortezomib Induced Hepatitis B Reactivation
Background. It has recently been reported that hepatitis B (HBV) reactivation often occurs after the use of rituximab and stem cell transplantation in patients with lymphoma who are hepatitis B surface antigen (HBsAg) negative. However, clinical data on HBV reactivation in multiple myeloma (MM) is limited to only a few reported cases. Bortezomib and lenalidomide have remarkable activity in MM w...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Canadian Journal of General Internal Medicine
سال: 2019
ISSN: 2369-1778,1911-1606
DOI: 10.22374/cjgim.v14i2.293